pharmaphorum July 29, 2024
Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.
The alliance with Health Innovation Oxford & Thames Valley (Oxford HIN) is focusing on Care for MDD, an app-based DTx co-developed by Otsuka and digital health specialist Click Therapeutics. It is an adapted version of a DTx that was recently approved by the FDA in the US under the Rejoyn brand.
Alongside Oxford HIN, Otsuka will monitor patient and healthcare practitioner feedback on the real-world use of Care for MDD, which combines a cognitive behavioural therapy (CBT) course with a cognitive-emotional training method known as Emotional Faces Memory...
Today's Sponsors
Today's Sponsor